Photoaging and Cosmetic Result with Artificial Daylight Photodynamic Therapy Using Methyl Aminolevulinate
DOI:
https://doi.org/10.2340/actadv.v105.43245Keywords:
Actinic Keratosis, methyl aminolevulinate, Photoaging, photodynamic therapy, telangiectasiaAbstract
Artificial daylight photodynamic therapy with methyl aminolevulinate is an effective and almost painless treatment approach for actinic keratoses. The objective of the prospective, non-interventional, multicentre study ArtLight (NCT05725213) was to gain comprehensive insights into the cosmetic effect of methyl aminolevulinate-artificial daylight photodynamic therapy in patients with actinic keratoses using different artificial daylight systems under real-world conditions. The study enrolled patients with Olsen grade 1 or 2 actinic keratoses on the face and scalp in Germany. Patients were treated with methyl aminolevulinate-artificial daylight photodynamic therapy. The cosmetic effect was assessed via photodamage parameters (global score for photoaging, mottled pigmentation, tactile roughness, telangiectasias, fine lines). Each photodamage variable was recorded on a 5-point scale (0–4). In total, 224 patients (median age: 75.0 years [range 50–91], 85.3% male, 62.5% Olsen grade 2, 55.4% treatment-naive) were treated with methyl aminolevulinate-artificial daylight photodynamic therapy. At month 3, all 5 parameters of photoaging were significantly reduced from baseline (p < 0.001). The majority of patients (81.3%) and investigators (83.6%) rated the cosmetic result as good or very good. Beyond effective eradication of actinic keratoses, field-directed methyl aminolevulinate-artificial daylight photodynamic therapy can improve photoaging symptoms, including tactile roughness, mottled pigmentation, telangiectasis, and fine lines. Thus methyl aminolevulinate-artificial daylight photodynamic therapy provides additional benefits, particularly for patients concerned with cosmetic outcomes during or after treatment.
Downloads
References
Eisen DB, Asgari MM, Bennett DD, Connolly SM, Dellavalle RP, Freeman EE, et al. Guidelines of care for the management of actinic keratosis. J Am Acad Dermatol 2021; 85: e209–e233.
https://doi.org/10.1016/j.jaad.2021.02.082 DOI: https://doi.org/10.1016/j.jaad.2021.02.082
Yaar M, Gilchrest BA. Photoageing: mechanism, prevention and therapy. Br J Dermatol 2007; 157: 874–887.
https://doi.org/10.1111/j.1365-2133.2007.08108.x DOI: https://doi.org/10.1111/j.1365-2133.2007.08108.x
Benjamin CL, Ullrich SE, Kripke ML, Ananthaswamy HN. p53 tumor suppressor gene: a critical molecular target for UV induction and prevention of skin cancer. Photochem Photobiol 2008; 84: 55–62.
https://doi.org/10.1111/j.1751-1097.2007.00213.x DOI: https://doi.org/10.1111/j.1751-1097.2007.00213.x
Schwarz T. 25 years of UV-induced immunosuppression mediated by T cells-from disregarded T suppressor cells to highly respected regulatory T cells. Photochem Photobiol 2008; 84: 10–18.
https://doi.org/10.1111/j.1751-1097.2007.00223.x DOI: https://doi.org/10.1111/j.1751-1097.2007.00223.x
Fuchs A, Marmur E. The kinetics of skin cancer: progression of actinic keratosis to squamous cell carcinoma. Dermatol Surg 2007; 33: 1099–1101. DOI: https://doi.org/10.1111/j.1524-4725.2007.33224.x
https://doi.org/10.1097/00042728-200709000-00010 DOI: https://doi.org/10.1097/00042728-200709000-00010
Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. Lancet 1988; 1: 795–797.
https://doi.org/10.1016/S0140-6736(88)91658-3 DOI: https://doi.org/10.1016/S0140-6736(88)91658-3
Abrouk M, Gianatasio C, Li Y, Waibel JS. Prospective study of intense pulsed light versus pulsed dye laser with or without blue light in the activation of PDT for the treatment of actinic keratosis and photodamage. Lasers Surg Med 2022; 54: 66–73.
https://doi.org/10.1002/lsm.23492 DOI: https://doi.org/10.1002/lsm.23492
George CD, Tokez S, Hollestein L, Pardo LM, Keurentjes AJ, Wakkee M, et al. Longitudinal assessment of the prevalence of actinic keratosis and extensive risk factor evaluation: an update from the Rotterdam Study. J Invest Dermatol 2023; 143: 2193–2203.e2112.
https://doi.org/10.1016/j.jid.2023.02.042 DOI: https://doi.org/10.1016/j.jid.2023.02.042
Szeimies RM, Gerritsen MJ, Gupta G, Ortonne JP, Serresi S, Bichel J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. J Am Acad Dermatol 2004; 51: 547–555.
https://doi.org/10.1016/j.jaad.2004.02.022 DOI: https://doi.org/10.1016/j.jaad.2004.02.022
Stockfleth E. The importance of treating the field in actinic keratosis. J Eur Acad Dermatol Venereol 2017; 31: 8–11.
https://doi.org/10.1111/jdv.14092 DOI: https://doi.org/10.1111/jdv.14092
Philipp-Dormston WG, Aschoff R, von Braunmühl T, Eigentler T, Haalck T, Thoms KM. [Decision criteria and patient characteristics for patient-oriented treatment of field cancerization: standardized algorithm for personalized treatment concepts]. Hautarzt 2021; 72: 314–320.
https://doi.org/10.1007/s00105-020-04731-y DOI: https://doi.org/10.1007/s00105-020-04731-y
Ruiz-Rodriguez R, Sanz-Sánchez T, Córdoba S. Photodynamic photorejuvenation. Dermatol Surg 2002; 28: 742–744; discussion 744.
https://doi.org/10.1046/j.1524-4725.2002.02018.x DOI: https://doi.org/10.1046/j.1524-4725.2002.02018.x
Szeimies RM, Lischner S, Philipp-Dormston W, Walker T, Hiepe-Wegener D, Feise K, et al. Photodynamic therapy for skin rejuvenation: treatment options – results of a consensus conference of an expert group for aesthetic photodynamic therapy. J Dtsch Dermatol Ges 2013; 11: 632–636.
https://doi.org/10.1111/ddg.12119 DOI: https://doi.org/10.1111/ddg.12119
Bento CO, Pantaleão L, de Souza MB, Vilar EAG, Luiz RR, Filho PJS, et al. Comparison of clinical and histologic findings in daylight photodynamic therapy for skin field cancerization: a randomized controlled four-arm study on physical methods-assisted delivery of methyl aminolevulinate. Photodiagnosis Photodyn Ther 2021; 35: 102404.
https://doi.org/10.1016/j.pdpdt.2021.102404 DOI: https://doi.org/10.1016/j.pdpdt.2021.102404
Karrer S, Szeimies RM, Philipp-Dormston WG, Gerber PA, Prager W, Datz E, et al. Repetitive daylight photodynamic therapy versus cryosurgery for prevention of actinic keratoses in photodamaged facial skin: a prospective, randomized controlled multicentre two-armed study. Acta Derm Venereol 2021; 101: adv00355.
https://doi.org/10.2340/00015555-3717 DOI: https://doi.org/10.2340/00015555-3717
Trave I, Salvi I, Serazzi FA, Schiavetti I, Luca L, Parodi A, et al. The impact of occlusive vs non-occlusive application of methyl aminolevulinate on the efficacy and tolerability of daylight photodynamic therapy for actinic keratosis. Photodiagnosis Photodyn Ther 2024; 46: 104049.
https://doi.org/10.1016/j.pdpdt.2024.104049 DOI: https://doi.org/10.1016/j.pdpdt.2024.104049
Arisi M, Rossi MT, Spiazzi L, Guasco Pisani E, Venturuzzo A, Rovati C, et al. A randomized split-face clinical trial of conventional vs indoor-daylight photodynamic therapy for the treatment of multiple actinic keratosis of the face and scalp and photoaging. J Dermatolog Treat 2022; 33: 2250–2256.
https://doi.org/10.1080/09546634.2021.1944594 DOI: https://doi.org/10.1080/09546634.2021.1944594
Gold MH. Therapeutic and aesthetic uses of photodynamic therapy part five of a five-part series: ALA-PDT and MAL-PDT what makes them different. J Clin Aesthet Dermatol 2009; 2: 44–47.
Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem Photobiol 1992; 55: 145–157.
https://doi.org/10.1111/j.1751-1097.1992.tb04222.x DOI: https://doi.org/10.1111/j.1751-1097.1992.tb04222.x
Philipp-Dormston WG, Brückner M, Hoffmann M, Baé M, Fränken J, Großmann B, et al. Artificial daylight photodynamic therapy using methyl aminolaevulinate in a real-world setting in Germany: results from the noninterventional study ArtLight. Br J Dermatol 2025; 192: 510–519.
https://doi.org/10.1093/bjd/ljae437 DOI: https://doi.org/10.1093/bjd/ljae437
Piccioni A, Fargnoli MC, Schoinas S, Suppa M, Frascione P, Ginebri A, et al. Efficacy and tolerability of 5-aminolevulinic acid 0.5% liposomal spray and intense pulsed light in wrinkle reduction of photodamaged skin. J Dermatolog Treat 2011; 22: 247–253.
https://doi.org/10.3109/09546634.2011.590791 DOI: https://doi.org/10.3109/09546634.2011.590791
Sanclemente G, Medina L, Villa JF, Barrera LM, Garcia HI. A prospective split-face double-blind randomized placebo-controlled trial to assess the efficacy of methyl aminolevulinate + red-light in patients with facial photodamage. J Eur Acad Dermatol Venereol 2011; 25: 49–58.
https://doi.org/10.1111/j.1468-3083.2010.03687.x DOI: https://doi.org/10.1111/j.1468-3083.2010.03687.x
Karrer S, Kohl E, Feise K, Hiepe-Wegener D, Lischner S, Philipp-Dormston W, et al. Photodynamic therapy for skin rejuvenation: review and summary of the literature – results of a consensus conference of an expert group for aesthetic photodynamic therapy. J Dtsch Dermatol Ges 2013; 11: 137–148.
https://doi.org/10.1111/j.1610-0387.2012.08046.x DOI: https://doi.org/10.1111/j.1610-0387.2012.08046.x
Philipp-Dormston WG. Photodynamic therapy for aesthetic-cosmetic indications. G Ital Dermatol Venereol 2018; 153: 817–826.
https://doi.org/10.23736/S0392-0488.18.05982-5 DOI: https://doi.org/10.23736/S0392-0488.18.05982-5
Touma D, Yaar M, Whitehead S, Konnikov N, Gilchrest BA. A trial of short incubation, broad-area photodynamic therapy for facial actinic keratoses and diffuse photodamage. Arch Dermatol 2004; 140: 33–40.
https://doi.org/10.1001/archderm.140.1.33 DOI: https://doi.org/10.1001/archderm.140.1.33
Ji J, Zhang LL, Ding HL, Wang HW, Huang Z, Wang XX, et al. Comparison of 5-aminolevulinic acid photodynamic therapy and red light for treatment of photoaging. Photodiagnosis Photodyn Ther 2014; 11: 118–121.
https://doi.org/10.1016/j.pdpdt.2014.02.007 DOI: https://doi.org/10.1016/j.pdpdt.2014.02.007
Park MY, Sohn S, Lee ES, Kim YC. Photorejuvenation induced by 5-aminolevulinic acid photodynamic therapy in patients with actinic keratosis: a histologic analysis. J Am Acad Dermatol 2010; 62: 85–95.
https://doi.org/10.1016/j.jaad.2009.06.025 DOI: https://doi.org/10.1016/j.jaad.2009.06.025
Szeimies RM, Torezan L, Niwa A, Valente N, Unger P, Kohl E, et al. Clinical, histopathological and immunohistochemical assessment of human skin field cancerization before and after photodynamic therapy. Br J Dermatol 2012; 167: 150–159.
https://doi.org/10.1111/j.1365-2133.2012.10887.x DOI: https://doi.org/10.1111/j.1365-2133.2012.10887.x
Issa MC, Piñeiro-Maceira J, Vieira MT, Olej B, Mandarim-de-Lacerda CA, Luiz RR, et al. Photorejuvenation with topical methyl aminolevulinate and red light: a randomized, prospective, clinical, histopathologic, and morphometric study. Dermatol Surg 2010; 36: 39–48.
https://doi.org/10.1111/j.1524-4725.2009.01385.x DOI: https://doi.org/10.1111/j.1524-4725.2009.01385.x
Orringer JS, Hammerberg C, Hamilton T, Johnson TM, Kang S, Sachs DL, et al. Molecular effects of photodynamic therapy for photoaging. Arch Dermatol 2008; 144: 1296–1302.
https://doi.org/10.1001/archderm.144.10.1296 DOI: https://doi.org/10.1001/archderm.144.10.1296
Bagazgoitia L, Cuevas Santos J, Juarranz A, Jaén P. Photodynamic therapy reduces the histological features of actinic damage and the expression of early oncogenic markers. Br J Dermatol 2011; 165: 144–151.
https://doi.org/10.1111/j.1365-2133.2011.10270.x DOI: https://doi.org/10.1111/j.1365-2133.2011.10270.x
Zane C, Capezzera R, Sala R, Venturini M, Calzavara-Pinton P. Clinical and echographic analysis of photodynamic therapy using methylaminolevulinate as sensitizer in the treatment of photodamaged facial skin. Lasers Surg Med 2007; 39: 203–209.
https://doi.org/10.1002/lsm.20470 DOI: https://doi.org/10.1002/lsm.20470
Zhang L, Zhao Z, Wang P, Zhang G, Wang B, Shi L, et al. Long-term improvement on photoaging after ALA photodynamic therapy for actinic keratosis: a retrospective study. Photodiagnosis Photodyn Ther 2021; 33: 102181.
https://doi.org/10.1016/j.pdpdt.2021.102181 DOI: https://doi.org/10.1016/j.pdpdt.2021.102181
Fargnoli MC, Ibbotson SH, Hunger RE, Rostain G, Gaastra MTW, Eibenschutz L, et al. Patient and physician satisfaction in an observational study with methyl aminolevulinate daylight photodynamic therapy in the treatment of multiple actinic keratoses of the face and scalp in six European countries. J Eur Acad Dermatol Venereol 2018; 32: 757–762.
https://doi.org/10.1111/jdv.14691 DOI: https://doi.org/10.1111/jdv.14691
Philipp-Dormston WG, Müller K, Novak B, Strömer K, Termeer C, Hammann U, et al. Patient-reported health outcomes in patients with non-melanoma skin cancer and actinic keratosis: results from a large-scale observational study analysing effects of diagnoses and disease progression. J Eur Acad Dermatol Venereol 2018; 32: 1138–1146.
https://doi.org/10.1111/jdv.14703 DOI: https://doi.org/10.1111/jdv.14703
Published
How to Cite
Issue
Section
Categories
License
Copyright (c) 2025 Rolf-Markus Szeimies, Matthias Brückner, Matthias Hoffmann, Melvin Baé, Jörg Fränken, Bernd Großmann, Uwe Paasch, Sven Quist, Berenice M. Lang, Rajeev Chavda, Wolfgang G. Philipp-Dormston
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
